SG11202012265SA - Systems and methods for preparing a polypeptide from a mixture - Google Patents

Systems and methods for preparing a polypeptide from a mixture

Info

Publication number
SG11202012265SA
SG11202012265SA SG11202012265SA SG11202012265SA SG11202012265SA SG 11202012265S A SG11202012265S A SG 11202012265SA SG 11202012265S A SG11202012265S A SG 11202012265SA SG 11202012265S A SG11202012265S A SG 11202012265SA SG 11202012265S A SG11202012265S A SG 11202012265SA
Authority
SG
Singapore
Prior art keywords
polypeptide
preparing
mixture
systems
methods
Prior art date
Application number
SG11202012265SA
Inventor
Isabelle Livigni
Stefanie Mcdermott
James Reilly
John Mattila
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of SG11202012265SA publication Critical patent/SG11202012265SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B01D15/18—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns
    • B01D15/1864—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns using two or more columns
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/30—Partition chromatography
    • B01D15/305—Hydrophilic interaction chromatography [HILIC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
SG11202012265SA 2018-07-02 2019-07-01 Systems and methods for preparing a polypeptide from a mixture SG11202012265SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862693024P 2018-07-02 2018-07-02
PCT/US2019/040148 WO2020010004A1 (en) 2018-07-02 2019-07-01 Use of multiple hydrophobic interaction chromatography for preparing a polypeptide from a mixture

Publications (1)

Publication Number Publication Date
SG11202012265SA true SG11202012265SA (en) 2021-01-28

Family

ID=67587924

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202012265SA SG11202012265SA (en) 2018-07-02 2019-07-01 Systems and methods for preparing a polypeptide from a mixture

Country Status (14)

Country Link
US (1) US11884698B2 (en)
EP (1) EP3818069A1 (en)
JP (1) JP2021529749A (en)
KR (1) KR20210027296A (en)
CN (1) CN112638931A (en)
AU (1) AU2019299321A1 (en)
BR (1) BR112020025624A2 (en)
CA (1) CA3103817A1 (en)
EA (1) EA202190163A1 (en)
IL (1) IL279564A (en)
MX (1) MX2020014205A (en)
SG (1) SG11202012265SA (en)
TW (1) TW202005694A (en)
WO (1) WO2020010004A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3031742A1 (en) 2016-08-16 2018-02-22 Regeneron Pharmaceuticals, Inc. Methods for quantitating individual antibodies from a mixture
DK3532838T3 (en) 2016-10-25 2022-07-04 Regeneron Pharma Methods and systems for chromatography data analysis
WO2022234412A1 (en) 2021-05-03 2022-11-10 Lupin Limited A process for purification of fc-fusion proteins

Family Cites Families (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4937188A (en) 1986-04-15 1990-06-26 Northeastern University Enzyme activity amplification method for increasing assay sensitivity
US5190864A (en) 1986-04-15 1993-03-02 Northeastern University Enzyme amplification by using free enzyme to release enzyme from an immobilized enzyme material
US4801726A (en) 1986-04-15 1989-01-31 Northeastern University Repetitive hit-and-run immunoassay and stable support-analyte conjugates; applied to T-2 toxin
US5412083A (en) 1992-04-16 1995-05-02 Northeastern University Carbohydrate heterobifunctional cross-linking reagent
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
AU4986596A (en) 1995-02-16 1996-09-04 Massachusetts Health Research Institute, Inc. Purified tetanus toxoid and toxin
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
DE69922740T2 (en) 1998-05-11 2005-12-08 Tosoh Corp., Shinnanyo Method for the separation of nucleic acids by liquid chromatography
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US7306799B2 (en) 1999-06-08 2007-12-11 Regeneron Pharmaceuticals, Inc. Use of VEGF inhibitors for treatment of eye disorders
US7303746B2 (en) 1999-06-08 2007-12-04 Regeneron Pharmaceuticals, Inc. Methods of treating eye disorders with modified chimeric polypeptides
PT1324776E (en) 2000-10-12 2009-12-23 Genentech Inc Reduced-viscosity concentrated protein formulations
US20020064860A1 (en) 2000-11-29 2002-05-30 Schering Corporation Method for purifying adenoviruses
US7101982B2 (en) 2001-03-30 2006-09-05 Immunex Corporation Control of ph transitions during chromatography
EP1585964A4 (en) 2002-08-28 2008-07-16 Introgen Therapeutics Inc Chromatographic methods for adenovirus purification
NZ539297A (en) 2002-09-13 2008-04-30 Biogen Idec Inc Method of purifying polypeptides by simulated moving bed chromatography
EP1614693A4 (en) 2003-03-31 2006-07-19 Kirin Brewery Purification of human monoclonal antibody and human polyclonal antibody
NZ544924A (en) 2003-06-27 2009-03-31 Biogen Idec Inc Modified binding molecules comprising connecting peptides
WO2005042569A1 (en) 2003-10-24 2005-05-12 Amgen, Inc. Process for purifying proteins in a hydrophobic interaction chromatography flow-through fraction
US8084032B2 (en) 2004-01-21 2011-12-27 Ajinomoto Co., Inc. Purification method which prevents denaturation of an antibody
NZ548126A (en) 2004-02-27 2009-10-30 Ge Healthcare Bio Sciences Ab A process for the purification of antibodies involving addition of a second resin
SE0400501D0 (en) 2004-02-27 2004-02-27 Amersham Biosciences Ab Antibody purification
SE0400886D0 (en) 2004-04-02 2004-04-02 Amersham Biosciences Ab Process of purification
WO2006020622A1 (en) 2004-08-09 2006-02-23 Guild Associates, Inc. Procedure for the fractionation of proteins by using sequential ion exchange and hydrophobic interaction chromatography as prefractionation steps before analysis by two dimensional electrophoresis
US7795405B2 (en) 2004-08-09 2010-09-14 Guild Associates, Inc. Procedure for the fractionation of proteins by using sequential ion exchange and hydrophobic interaction chromatography as prefractionation steps before analysis by two dimensional electrophoresis
US7714112B2 (en) 2004-10-21 2010-05-11 Ge Healthcare Bio-Sciences Ab Method of antibody purification
WO2006088650A2 (en) 2005-02-02 2006-08-24 Regeneron Pharmaceuticals, Inc. Method of treating eye injury with local administration of a vegf inhibitor
EP1775001A1 (en) 2005-10-13 2007-04-18 Xendo Holding B.V. Device for chromatographic separations
US20080299671A1 (en) 2005-12-02 2008-12-04 Ge Healthcare Bio-Sciences Ab Hydrophobic Interaction Chromatography
KR20080104160A (en) 2006-03-28 2008-12-01 에프. 호프만-라 로슈 아게 Anti-igf-1r human monoclonal antibody formulation
TW201333030A (en) 2006-04-05 2013-08-16 Abbott Biotech Ltd Antibody purification
KR101406811B1 (en) 2006-06-16 2014-06-12 리제너론 파마슈티칼스 인코포레이티드 Vegf antagonist formulations suitable for intravitreal administration
WO2008028974A1 (en) 2006-09-08 2008-03-13 Novo Nordisk A/S Methods of optimizing chromatographic separation of polypeptides
US8969532B2 (en) 2006-10-03 2015-03-03 Novo Nordisk A/S Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
US20080299545A1 (en) 2007-03-06 2008-12-04 Shuyuan Zhang Chromatographic methods for assessing adenovirus purity
US8003364B2 (en) 2007-05-14 2011-08-23 Bavarian Nordic A/S Purification of vaccinia viruses using hydrophobic interaction chromatography
JP5571552B2 (en) 2007-06-15 2014-08-13 ジーイー・ヘルスケア・バイオ−サイエンシズ・アーベー Chromatographic method
WO2009058769A1 (en) 2007-10-30 2009-05-07 Schering Corporation Purification of antibodies containing hydrophobic variants
EP2252952B1 (en) 2008-01-25 2019-03-13 Biogen MA Inc. Automated system and method for monitoring chromatography column performance, and applications thereof
US8410928B2 (en) 2008-08-15 2013-04-02 Biogen Idec Ma Inc. Systems and methods for evaluating chromatography column performance
US20100069617A1 (en) 2008-09-12 2010-03-18 Ge Healthcare Bio-Sciences Ab Enhanced protein aggregate removal by mixed mode chromatography on hydrophobic interaction media in the presence of protein-excluded zwitterions
TW201024318A (en) 2008-10-20 2010-07-01 Abbott Lab Isolation and purification of antibodies using protein A affinity chromatography
EP2346897A2 (en) 2008-10-20 2011-07-27 Abbott Laboratories Viral inactivation during purification of antibodies
KR20120038406A (en) 2009-05-04 2012-04-23 애보트 바이오테크놀로지 리미티드 Stable high protein concentration formulations of human anti-tnf-alpha antibodies
WO2010148143A1 (en) 2009-06-16 2010-12-23 Genzyme Corporation Improved methods for purification of recombinant aav vectors
US8821879B2 (en) 2009-09-04 2014-09-02 Xoma Technology Ltd. Anti-botulism antibody coformulations
EP3037104B1 (en) 2009-10-20 2020-05-27 AbbVie Inc. Isolation and purification of anti-il-13 antibodies using protein a affinity chromatography
US8246833B2 (en) 2009-12-17 2012-08-21 Ge Healthcare Bio-Sciences Ab Chromatography column and maintenance method
AU2011214361C1 (en) 2010-02-12 2016-01-14 Dpx Holdings B.V. Single unit antibody purification
WO2012030512A1 (en) * 2010-09-03 2012-03-08 Percivia Llc. Flow-through protein purification process
EP2618904A1 (en) * 2010-09-20 2013-07-31 AbbVie Inc. Purification of antibodies using simulated moving bed chromatography
KR101841527B1 (en) 2010-11-11 2018-03-23 애브비 바이오테크놀로지 리미티드 IMPROVED HIGH CONCENTRATION ANTI-TNFα ANTIBODY LIQUID FORMULATIONS
EP2652491B1 (en) 2010-12-15 2017-11-29 Baxalta GmbH Eluate collection using conductivity gradient
US9943594B2 (en) 2011-10-11 2018-04-17 Sanofi Biotechnology Methods for the treatment of rheumatoid arthritis
TWI589299B (en) 2011-10-11 2017-07-01 再生元醫藥公司 Compositions for the treatment of rheumatoid arthritis and methods of using same
EP2773439A4 (en) 2011-10-31 2015-07-01 Merck Sharp & Dohme Chromatography process for resolving heterogeneous antibody aggregates
SI2780368T1 (en) 2011-11-14 2018-04-30 Regeneron Pharmaceuticals, Inc. Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing gdf8 and/or activin a
MX2014005885A (en) 2011-11-21 2014-09-04 Genentech Inc Purification of anti-c-met antibodies.
CN103998469B (en) 2011-12-15 2018-01-02 普雷斯蒂奇生物制药私人有限公司 Antibody purification process
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
EP2656892A1 (en) * 2012-04-23 2013-10-30 Merck Patent GmbH Chromatography method
US20140154270A1 (en) 2012-05-21 2014-06-05 Chen Wang Purification of non-human antibodies using kosmotropic salt enhanced protein a affinity chromatography
WO2013177115A2 (en) 2012-05-21 2013-11-28 Abbvie Inc. Novel purification of human, humanized, or chimeric antibodies using protein a affinity chromatography
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
WO2014025771A2 (en) 2012-08-06 2014-02-13 Biogen Idec Ma Inc. Methods and compositions for inactivating enveloped viruses
US9650411B2 (en) 2012-08-07 2017-05-16 Kyowa Hakko Kirin Co., Ltd. Method of purifying protein
WO2014100143A2 (en) 2012-12-20 2014-06-26 Medimmune, Llc Liquid antibody formulation with improved aggregation properties
RU2768003C2 (en) 2013-03-08 2022-03-22 Джензим Корпорейшн Integrated continuous production of therapeutic protein-based medicinal agents
CA2905010A1 (en) 2013-03-12 2014-09-18 Abbvie Inc. Human antibodies that bind human tnf-alpha and methods of preparing the same
US10023608B1 (en) 2013-03-13 2018-07-17 Amgen Inc. Protein purification methods to remove impurities
AU2013384204B2 (en) 2013-03-14 2017-03-16 Abbvie Inc. Low acidic species compositions and methods for producing and using the same
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
DK2970378T3 (en) 2013-03-15 2021-08-23 Biogen Ma Inc HYDROPHOB INTERACTION PROTEIN CHROMATOGRAPHY UNDER SALT-FREE CONDITIONS
ES2834113T3 (en) 2013-03-15 2021-06-16 H Lundbeck As Antibody purification and purity monitoring
LT2981822T (en) 2013-05-06 2020-12-28 Scholar Rock, Inc. Compositions and methods for growth factor modulation
TWI682780B (en) 2013-05-30 2020-01-21 美商再生元醫藥公司 Use of a pharmaceutical composition for the manufacture of a medicament for treating autosomal dominant hypercholesterolemia associated with pcsk9 gain-of-function mutations
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
TWI633891B (en) 2013-06-04 2018-09-01 再生元醫藥公司 Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r inhibitor
KR101569783B1 (en) 2013-06-05 2015-11-19 한화케미칼 주식회사 A Method of Antibody Purification
US9150938B2 (en) 2013-06-12 2015-10-06 Orochem Technologies, Inc. Tagatose production from deproteinized whey and purification by continuous chromatography
AR096713A1 (en) 2013-06-25 2016-01-27 Cadila Healthcare Ltd PURIFICATION PROCESS FOR MONOCLONAL ANTIBODIES
CA2922832A1 (en) 2013-09-05 2015-03-12 Genentech, Inc. Method for chromatography reuse
CN105722992B (en) 2013-09-13 2021-04-20 豪夫迈·罗氏有限公司 Compositions and methods for detecting and quantifying host cell proteins in cell lines and recombinant polypeptide products
EP4331605A3 (en) 2013-09-13 2024-05-22 F. Hoffmann-La Roche AG Methods and compositions comprising purified recombinant polypeptides
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
WO2015061526A1 (en) 2013-10-25 2015-04-30 Medimmune, Llc Antibody purification
US10115576B2 (en) 2013-12-12 2018-10-30 Waters Technologies Corporation Method and an apparatus for analyzing a complex sample
JO3701B1 (en) 2014-05-23 2021-01-31 Regeneron Pharma Human antibodies to middle east respiratory syndrome – coronavirus spike protein
FR3025515B1 (en) 2014-09-05 2016-09-09 Lab Francais Du Fractionnement PROCESS FOR PURIFYING MONOCLONAL ANTIBODY
TW201628649A (en) 2014-10-09 2016-08-16 再生元醫藥公司 Process for reducing subvisible particles in a pharmaceutical formulation
WO2016089886A2 (en) 2014-12-02 2016-06-09 Regeneron Pharmaceuticals, Inc. Methods for treating dry eye disease by administering an il-6r antagonist
US10696735B2 (en) 2015-01-21 2020-06-30 Outlook Therapeutics, Inc. Modulation of charge variants in a monoclonal antibody composition
TWI710573B (en) 2015-01-26 2020-11-21 美商再生元醫藥公司 Human antibodies to ebola virus glycoprotein
TWI756187B (en) 2015-10-09 2022-03-01 美商再生元醫藥公司 Anti-lag3 antibodies and uses thereof
SI3394103T1 (en) 2015-12-22 2023-10-30 Regeneron Pharmaceuticals, Inc. Combination of anti-pd-1 antibodies and bispecific anti-cd20/anti-cd3 antibodies to treat cancer
CA3009322A1 (en) 2015-12-22 2017-06-29 Regeneron Pharmaceuticals, Inc. Bispecific anti-cd20/anti-cd3 antibodies to treat acute lymphoblastic leukemia
EP3184119A1 (en) 2015-12-23 2017-06-28 Themis Bioscience GmbH Chromatography based purification strategies for measles scaffold based viruses
GB201602938D0 (en) 2016-02-19 2016-04-06 Ucb Biopharma Sprl Protein purification
AU2017284202B2 (en) 2016-06-14 2021-11-04 Biogen Ma Inc. Hydrophobic interaction chromatography for purification of oligonucleotides
WO2018027195A1 (en) 2016-08-05 2018-02-08 Abbvie Biotherapeutics Inc. Compositions containing reduced amounts of daclizumab acidic isoforms and methods for preparing the same
HUE054420T2 (en) * 2016-10-17 2021-09-28 Enzene Biosciences Ltd Continuous process for reducing heterogeneity of therapeutic protein
US10626376B2 (en) 2016-11-14 2020-04-21 St. Jude Children's Research Hospital Method for isolating and purifying adeno-associated virus particles using salt
WO2018105982A1 (en) 2016-12-05 2018-06-14 한미약품 주식회사 Improved purification method of recombinant protein
MA49962A (en) 2017-08-22 2020-07-01 Biogen Ma Inc PROCESSES FOR PURIFYING ANTIBODIES PRESENTING REDUCED AGGREGATES WITH HIGH MOLECULAR WEIGHT
WO2019178489A1 (en) 2018-03-16 2019-09-19 Bristol-Myers Squibb Company Metabolic enzyme activity and disulfide bond reduction during protein production
WO2019178495A1 (en) 2018-03-16 2019-09-19 Biogen Ma Inc. Methods for purifying recombinant adeno-associated viruses
KR20200136464A (en) 2018-03-29 2020-12-07 브리스톨-마이어스 스큅 컴퍼니 Method for purifying monomeric monoclonal antibodies
CN112566930A (en) 2018-06-19 2021-03-26 百时美施贵宝公司 Method for purifying proteins using chromatography
EP3826743A4 (en) 2018-07-25 2022-09-14 Merck Sharp & Dohme Corp. Methods of separating host cell lipases from a production protein in chromatographic processes
JP2021534151A (en) 2018-08-15 2021-12-09 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Protein fragmentation control strategy by reoxidation in downstream chromatography
EP3876996A1 (en) 2018-11-05 2021-09-15 Bristol-Myers Squibb Company Method for purifying pegylated protein
WO2020172658A1 (en) 2019-02-24 2020-08-27 Bristol-Myers Squibb Company Methods of isolating a protein
US20220042954A1 (en) 2019-03-29 2022-02-10 Bristol-Myers Squibb Company Methods of measuring hydrophobicity of chromatographic resins
CN114173827A (en) 2019-06-28 2022-03-11 武田药品工业株式会社 Adeno-associated virus purification method

Also Published As

Publication number Publication date
WO2020010004A1 (en) 2020-01-09
MX2020014205A (en) 2021-05-27
KR20210027296A (en) 2021-03-10
US20200002373A1 (en) 2020-01-02
EA202190163A1 (en) 2021-03-30
EP3818069A1 (en) 2021-05-12
AU2019299321A1 (en) 2021-01-07
JP2021529749A (en) 2021-11-04
TW202005694A (en) 2020-02-01
IL279564A (en) 2021-01-31
CA3103817A1 (en) 2020-01-09
BR112020025624A2 (en) 2021-03-23
CN112638931A (en) 2021-04-09
US11884698B2 (en) 2024-01-30

Similar Documents

Publication Publication Date Title
GB202003509D0 (en) Systems and methods for aircraft
SG11202110655UA (en) Systems and methods for karyotyping by sequencing
SG11202106166TA (en) Peptide binder
SG11202012265SA (en) Systems and methods for preparing a polypeptide from a mixture
IL283385A (en) Modified gip peptide analogues
EP3796851C0 (en) Systems for anchor placement
IL281552A (en) Methods and means for preparing a library for sequencing
GB201914224D0 (en) Systems and methods for aircraft
SG11202007045SA (en) Fuel system
IL289477A (en) Suturing system
IL283577A (en) Systems and methods for facilitating clone selection
GB2585826B (en) Systems and methods for activating functionality
GB201913411D0 (en) Aircraft system
GB201810052D0 (en) Polypeptide
GB201914223D0 (en) Systems and methods for aircraft
GB201914219D0 (en) Systems and methods for aircraft
GB201914220D0 (en) Systems and methods for aircraft
GB201914225D0 (en) Systems and methods for aircraft
GB201806655D0 (en) Polypeptide
GB201914227D0 (en) Systems and methods for aircrafts
GB201915221D0 (en) Aircraft system
GB201915220D0 (en) Aircraft system
GB201915713D0 (en) Systems and methods for activating functionality
GB201809130D0 (en) A flying theatre system
SG10201912112SA (en) System and method for blasting parameter selection